Infectious Disease Alert – May 1, 2008
May 1, 2008
View Issues
-
Persistence of HIV in Gut-associated Lymphoid Tissue with Antiretroviral Therapy
Eight hiv-infected patients (mean CD4+ t cell count 622 cells/uL) who had been receiving effective HAART for an average of 8.4 years were included in this study. PBMCs were obtained by leukapheresis and endoscopic terminal ileum biopsies were performed to obtain samples of Gut-Associated Lymphoid Tissue (GALT). -
Doripenem (Doribax): A Novel Carbapenem
In 1985, the newly fda-approved antimicrobial agent, Primaxin® (imipenem/cilastatin), introduced a new class of drugs known as carbapenems. This new class provided benefits as well as unwanted side effects. Carbapenems work similarly to other â-lactam antibiotics, but with substantially broader-spectrum of activity and better penetration into bacterial cell walls to prevent synthesis. -
Viral Influenza Complications
Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world. -
Updates by Carol A. Kemper, MD, FACP
Trauma in wartime is especially high risk given the nature of the injuries, the high risk of infection, and the limited access to optimal medical care. -
Pharmacology Watch: FDA Drug Approval to Change its Ways?
In This Issue: FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions. -
Clinical Briefs in Primary Care supplement